Skip to Content

Daiichi Sankyo Co Ltd DSKYF

Morningstar Rating
$35.20 −2.72 (7.17%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DSKYF is trading at a 165% premium.
Price
$38.02
Fair Value
$39.98
Uncertainty
Medium
1-Star Price
$22.12
5-Star Price
$57.94
Economic Moat
Qqmypvh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DSKYF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$37.92
Day Range
$35.2039.48
52-Week Range
$23.4540.35
Bid/Ask
$35.15 / $39.67
Market Cap
$67.20 Bil
Volume/Avg
798 / 6,021

Key Statistics

Price/Earnings (Normalized)
49.82
Price/Sales
6.09
Dividend Yield (Trailing)
0.93%
Dividend Yield (Forward)
1.08%
Total Yield
0.93%

Company Profile

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
18,726

Competitors

Valuation

Metric
DSKYF
4519
AZN
Price/Earnings (Normalized)
49.8231.0221.30
Price/Book Value
6.055.916.52
Price/Sales
6.099.375.16
Price/Cash Flow
37.2529.2024.36
Price/Earnings
DSKYF
4519
AZN

Financial Strength

Metric
DSKYF
4519
AZN
Quick Ratio
2.324.210.70
Current Ratio
3.015.530.89
Interest Coverage
35.145.32
Quick Ratio
DSKYF
4519
AZN

Profitability

Metric
DSKYF
4519
AZN
Return on Assets (Normalized)
6.99%17.64%59.78%
Return on Equity (Normalized)
12.93%21.05%157.53%
Return on Invested Capital (Normalized)
10.69%20.98%88.21%
Return on Assets
DSKYF
4519
AZN
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
TnzwphtrtPdm$772.1 Bil
Johnson & Johnson
JNJ
RcnfzbmcLhzj$372.3 Bil
Merck & Co Inc
MRK
MmzmbvsjxFwj$318.6 Bil
AbbVie Inc
ABBV
StphctwkJhtfq$304.3 Bil
Roche Holding AG ADR
RHHBY
ZltwsttjyqDjrlp$253.0 Bil
AstraZeneca PLC ADR
AZN
NghnqzvylVwvf$243.0 Bil
Novartis AG ADR
NVS
SzvvjypmCpy$217.8 Bil
Amgen Inc
AMGN
FnmvnzjprJkvz$177.7 Bil
Pfizer Inc
PFE
PslmltsHmxwk$169.8 Bil
Sanofi SA ADR
SNY
MrjcyqvjVkqr$126.3 Bil

Sponsor Center